DailyIQ
Last updatedjust now

RVTY·Revvity, Inc.

$155.08
-0.53 (-0.34%)
Overnight$155.08+0.00 (+0.00%)
High
$157.46
Open
$156.44
Market Cap
17.35B
52W High
$166.25
Low
$153.10
P. Close
$155.08
P/E
73.02
52W Low
$81.22
Fwd P/E
26.31
DailyIQ Est.
$144.28
Inst. Ownership
42.0%
Short Interest
5.63%
Days to Cover
2.4
Div. Yield
0.18%
Next Ex-Div
~Oct 16
Technical Score (1D)
84
BULLISH
News Sentiment
51
MIXED
On Oct 13, Revvity announced it would present at several investor conferences. On Oct 13, the company said it would attend multiple investor conferences. On Oct 13, Revvity aimed to engage with investors and stakeholders through these events. On Oct 13, no specific financial guidance or performance details were disclosed. On Oct 13, the announcement was reported by the company itself.
LOW TARGET
$110 -29.1%
2 analysts
MEAN TARGET
$142 -8.7%
17 analysts
HIGH TARGET
$165 +6.4%
8 analysts
PRICE RANGE
$110.00 - $165.00
SB / B / H / S / SS
5/8/12/1/1
DAILYIQ EST.
$144.28 (-7.0%)
Sector
Healthcare
Industry
Diagnostics & Research
Exchange
NYQ
Country
United States
Symbol
RVTY
Description
Revvity, Inc. is a provider of health science solutions, offering a comprehensive suite of technologies and services to support research, diagnostics, and drug discovery. The company's core business centers around providing instruments, reagents, software, and related services that facilitate genetic testing and analysis. Revvity's offerings are utilized in early detection of genetic disorders, infectious disease testing, and genomic workflows, targeting a diverse customer base including pharmaceutical companies, research institutions, and healthcare providers. With a wide array of branded products and services, Revvity enables critical applications such as newborn screening, oncology research, and immunodiagnostics. Formerly known as PerkinElmer, the company has a long history, dating back to 1937, and is headquartered in Waltham, Massachusetts.
Bought (1Y)
0 shares
$0
Sold (1Y)
9,163 shares
$1.3M
Gonzales AnitaVP and CAO
Sell84 shares2026-10-01
Krakowiak MaxwellPlease See Remarks
Sell1,631 shares2026-09-21
Vohra Tajinder SPlease See Remarks
Sell7,330 shares2026-09-16
MICHAS ALEXIS P-
Gift285 shares2026-08-25
Goldberg Joel SPlease See Remarks
Gift27,785 shares2026-08-14
66/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
85.2%
Net Margin
8.4%
Revenue CAGR
4.0%
Current Ratio
1.68x
Debt / Equity
0.44x
Return on Equity
3.3%
Earnings Summary
Revvity, Inc. is a provider of health science solutions, offering instruments, reagents, software, and services for genetic testing and research, headquartered in Waltham, Massachusetts. Over the last two quarters, Revvity reported EPS of $1.18 in Q2 2025 and $1.18 in Q3 2025, both beating estimates of $1.14 and $1.14 respectively, while revenue rose from $720.28 million to $698.95 million, a modest decline; Q4 2025 EPS of $1.70 beat the $1.58 estimate and revenue of $772.06 million slightly exceeded the $776.64 million estimate. Historically, the company has shown a pattern of EPS beats in consecutive quarters, with revenue growth remaining relatively flat but generally positive, indicating stable profitability. Recent news includes multiple brokerage upgrades and price target increases in early October 2026, reflecting analyst confidence in Revvity’s growth trajectory and operational gains.

EPS

EstBeatMiss
$0.96$1.17$1.38$1.59$1.80Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$1.30 - -
Q2'26$1.25$1.41+13.1%
Q1'26$1.23$1.06-13.8%
Q4'25$1.58$1.70+7.5%
Q3'25$1.14$1.18+3.6%
Q2'25$1.14$1.18+3.4%

Revenue

EstBeatMiss
$687M$713M$738M$763M$788MQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$712M - -
Q2'26$723M$730M+0.9%
Q1'26$736M$711M-3.4%
Q4'25$777M$772M-0.6%
Q3'25 - $699M -
Q2'25 - $720M -

Market Data

RVTY Stock Snapshot

BULLISH84/100
$155.08+$0.00 (0.0%)
Market cap
17.35B
P/E ratio
73.0
Day range
$153.10 – $157.46
News sentiment
51/100 · Neutral
Analyst target
$141.53 (-8.7%)
Consensus
Hold · 27 analysts
52-week range+90.9% off low · -6.7% from high
$81.22$166.25
Price $155.08 DailyIQ Est. $144.28

Trend, momentum and range position line up bullish on RVTY at the moment. The stock is liquid enough that positioning changes get absorbed without distorting the trend.

Reverse DCF

What growth is priced into RVTY?

RICH

At today's price, Revvity, Inc. needs to grow free cash flow about 26.3% a year for the next 10 years to justify its valuation at a 8.88% cost of capital. Over its actual history it has compounded free cash flow at 7.0% a year, so the market is asking for 19.3 percentage points above its own delivered rate. On that basis RVTY looks priced above what its own growth record supports.

Implied FCF growth
26.3%
Historical FCF CAGR
7.0%
Growth gap
+19.3 pts
Verdict
RICH
Discount rate (WACC)
8.88%
Beta
0.97

Behaviour On Record

What RVTY's own history says about today's numbers

Realized volatility (21d)
47.9% 97th pct
Below its peak
-23.3%
vs 200-day average
+43.5%
Up days (1y)
53%

Revvity, Inc. is currently running 47.9% annualised volatility over the last 21 sessions. Measured against RVTY's own 13 years of daily returns rather than a market-wide average, that is the 97th percentile — an extreme by its own standards, against a typical reading of 25.4%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

RVTY is trading -23.3% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -23.3%, and the deepest was -43.2% in 2023. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits +43.5% from its 200-day moving average. Against every other day in its history, that gap ranks at the 100th percentile — a wider gap than this stock usually carries. Over the past year RVTY closed higher on 53% of sessions, and it is currently 1 session into a rising streak.

On October specifically: over 13 years of records, RVTY finished the month higher 9 of 13 times, with a median return of +2.2% and an average of -1.0%. Its strongest month historically has been July at +5.0% on average, its weakest February at -3.3%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: RVTY has opened more than 2% away from the prior close in 154 of 3,266 sessions (4.7% of the time), with the largest gaps running +7.6% and -12.9%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, RVTY moved an average of 5.5% in the session after earnings, closing higher 2 of those 3 times, with a median move of +3.3% and a largest of +7.4%.

All figures computed from 3,267 daily closes between 2013-10-14 and 2026-10-09, split-adjusted, recomputed daily. Percentiles are against RVTY's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of RVTY's sector?

Revvity, Inc. sits in the Health Care sector, currently ranked 4th of 12 GICS sectors by relative-strength rotation score (improving).

Sector rank
#4 of 12
Sector state
Improving
Sector rotation score
73

Analyst Rating Changes

Are analysts turning bullish or bearish on RVTY?

TD Cowen most recently reiterated its rating on Revvity, Inc. to Buy on Oct 13, 2026 with a price target of $175 (from $130). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
TD Cowen — Buy
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Oct 13, 2026TD CowenMaintainedBuy$130 → $175
Oct 7, 2026BarclaysMaintainedEqual-Weight$115 → $160
Oct 6, 2026William BlairInitiatedOutperform-
Sep 4, 2026KeybancMaintainedOverweight$125 → $165
Sep 1, 2026RBC CapitalInitiatedSector Perform$135
Aug 5, 2026Evercore ISI GroupMaintainedOutperform$125 → $126
Jul 6, 2026Evercore ISI GroupMaintainedOutperform$110 → $125
May 7, 2026BarclaysMaintainedEqual-Weight$95 → $105
May 6, 2026JP MorganMaintainedNeutral$96 → $90
May 6, 2026TD CowenMaintainedBuy$115 → $120
May 6, 2026StifelMaintainedHold$110 → $100
May 4, 2026BairdMaintainedOutperform$129 → $125

Peers & ETF holders

RVTY peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

51/100
Strong NegativeNeutralStrong Positive
MIXED

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Revvity, Inc. (NYSE: RVTY) announced it would present at the 2026 Jefferies Global Healthcare Conference on November 17 and the 9th Annual Evercore Healthcare Conference on December 2. The company’s CEO, Prahlad Singh, will lead the presentations, providing updates on strategic priorities and future initiatives. Live audio webcasts will be streamed during the events, with recordings posted on the company’s Investor Relations site for at least 30 days. The announcement is a routine disclosure of upcoming investor engagement activities and does not indicate any new financial guidance or operational changes.
What did this article say?
TD Cowen increased its price target for Revvity (RVTY) to $175 from $130, reflecting a more optimistic view of the company’s prospects. The upgrade comes amid a broader positive sentiment toward Revvity’s business model and growth potential. Analysts noted that the new target aligns with a stronger earnings outlook and favorable market conditions for the company.
What did this article say?
Baird lifted its price target for Revvity (RVTY) from $144 to $164, reflecting a more optimistic view of the company’s prospects. The brokerage noted Revvity’s average rating of hold and a mean target of $140.07 among analysts. The upgrade signals confidence in Revvity’s growth trajectory and potential to outperform peers. This adjustment may influence investor sentiment and trading activity. The move aligns with broader positive market expectations for the company.
What did this article say?
Evercore ISI increased its price target for Revvity (RVTY) from $125 to $165, reflecting a more optimistic view of the company’s prospects. The upgrade comes amid a broader assessment that Revvity’s business model and growth trajectory justify a higher valuation. Analysts noted the company’s strong market position and potential for future earnings expansion as key drivers behind the revised target.
What did this article say?
Barclays analyst Luke Sergott upgraded Revvity’s rating to Equal‑Weight and lifted the price target from $115 to $160. The upgrade reflects confidence in the company’s growth prospects and its competitive positioning in the cloud‑based revenue‑management market. The move signals a positive outlook for investors and may support the stock’s valuation.
What did this article say?
Revvity is set to report its third‑quarter earnings next month, with analysts forecasting a high single‑digit increase in net income. The company’s guidance suggests continued momentum in its subscription‑based services. Investors anticipate the results to confirm Revvity’s growth trajectory and potentially lift the stock.
What did this article say?
William Blair analyst Matt Larew initiated coverage of Revvity (NYSE:RVTY) on October 6, assigning an Outperform rating. The firm cited the company’s strong market position and recent operational improvements as key drivers. The coverage launch signals confidence in Revvity’s growth prospects and may influence investor sentiment.
What did this article say?
William Blair lifted Revvity (RVTY) to Outperform after the company approached its 52‑week high. The brokerage cited strong AI tailwinds and a recovering life‑sciences market as key catalysts. Analyst projections suggest the stock could climb an additional 20% from current levels. The upgrade reflects confidence in Revvity’s product pipeline and market positioning. The move signals a positive outlook for investors seeking exposure to AI‑driven healthcare solutions.
What did this article say?
Barclays increased its price target for Revvity (RVTY) from $115 to $160 while keeping an equal‑weight rating. The upgrade reflects a more optimistic view of the company’s growth prospects and earnings outlook. The new target suggests a potential upside for investors, though the rating remains unchanged.
What did this article say?
Revvity, Inc. (NYSE: RVTY) announced it will host its 2026 Investor Day on Friday, November 13 at 9:00 a.m. ET. The event will feature presentations from senior management covering key business initiatives, operational achievements, and financial outlook. A webcast and replay will be available on the company’s Investor Relations website. The announcement is a routine corporate event with no immediate material impact on the company’s financials or operations.

Technical Analysis

Real-time indicators across multiple timeframes

84
BULLISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $4.82B combined position · 16 adding, 9 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▼ Sell13,160,89711.77%$1.27B2026-01-29
BlackRock, Inc.▲ Buy7,658,3696.85%$852.07M2026-08-07
Janus Henderson Group plc▲ Buy8,348,1277.46%$731.39M2026-05-18
Geode Capital Management, LLC▲ Buy2,955,2272.64%$328.20M2026-08-12
Morgan Stanley▼ Sell2,574,8262.30%$286.48M2026-08-13
Invesco Ltd.▼ Sell2,424,9702.17%$269.80M2026-08-14
Neuberger Berman Group LLC▲ Buy1,876,0411.68%$208.73M2026-08-13
Citadel Advisors LLC▲ Buy1,457,3351.30%$162.14M2026-09-02
Northern Trust Corp▲ Buy944,5630.84%$105.09M2026-08-13
Goldman Sachs Group Inc▲ Buy900,3510.80%$100.17M2026-08-14
Wellington Management Group LLP▲ Buy865,5750.77%$96.30M2026-08-14
Norges Bank▲ Buy864,4890.77%$96.18M2026-08-12
Bank of America Corp▼ Sell782,9970.70%$87.12M2026-08-14
JPMorgan Chase & Co▲ Buy481,9550.43%$54.18M2026-08-12
FMR LLC (Fidelity)▲ Buy465,6420.42%$51.81M2026-08-13
Artisan Partners Limited Partnership▼ Sell200,6160.18%$22.32M2026-08-13
Citigroup Inc▲ Buy137,3720.12%$15.28M2026-08-03
AQR Capital Management LLC▲ Buy125,4870.11%$13.96M2026-08-14
Marshall Wace, LLP▲ Buy113,5520.10%$12.63M2026-08-13
AllianceBernstein L.P.▼ Sell113,3370.10%$9.93M2026-08-14
Millennium Management LLC▼ Sell75,2290.07%$8.37M2026-08-14
Wells Fargo & Company▲ Buy70,1520.06%$7.81M2026-08-14
Prudential Financial Inc▲ Buy69,5870.06%$7.74M2026-08-12
Gotham Asset Management, LLC▼ Sell68,5890.06%$7.63M2026-08-14
Balyasny Asset Management L.P.▼ Sell63,0560.06%$7.02M2026-08-14
Q2 2026 flow:4.05M sh bought ($450.70M)1.76M sh sold ($195.87M)net +2.29M sh (+$254.83M)
Congressional Trading Activity
14 disclosed trades · ~$185.5K est. traded value · 9 buys, 5 sells
MemberChamberStateTypeAmountTradedFiled
Gilbert CisnerosHouseCA31▼ Sell$15K - $50K2026-09-092026-10-12
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2026-09-042026-10-12
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2026-09-032026-10-12
Gilbert CisnerosHouseCA31▲ Buy$15K - $50K2026-05-042026-06-08
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2026-05-012026-05-08
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-09-122025-10-10
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-08-132025-09-12
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-07-232025-08-14
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-07-222025-08-13
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-06-172025-08-13
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-06-112025-07-10
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-05-282025-06-06
April McClain DelaneyHouseMD06▼ Sell$15K - $50K2025-02-282025-03-20
Rob BresnahanHousePA08▲ Buy$1K - $15K2025-02-252025-03-27